An observational study in Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 3 sites in Sweden. Per ClinicalTrials.gov, last updated 2012-01-31.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer · Observational
The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 472 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Transplantation patients treated with sirolimus.
Exclusion Criteria:
Sirolimus
Drug: Sirolimus
Transplantation patients treated with sirolimus who consent to participate in the study (register)
Also known as: Rapamune
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wyeth is now a wholly owned subsidiary of Pfizer